Journal of Inflammation Research最新文献

{"title":"Effects of Combined Shinbaro and Celecoxib in a Complete Freund's Adjuvant-Induced Inflammatory Pain Mouse Model.","authors":"Jae-Hwan Jang, Yurim Song, Seok Hee Han, Bo Ram Choi, Yoon Jae Lee, In-Hyuk Ha","doi":"10.2147/JIR.S500345","DOIUrl":"10.2147/JIR.S500345","url":null,"abstract":"<p><strong>Purpose: </strong>Persistent inflammation resulting from injury, infection, or arthritis contributes to both peripheral and central sensitization. Various combinations of natural extracts have been explored to minimize the side effects associated with conventional medications. Shinbaro, which has traditionally been used in Eastern medicine to treat inflammatory conditions, was chosen due to its known anti-inflammatory properties. However, previous studies have not yet investigated the combined administration of celecoxib and Shinbaro for their anti-inflammatory and analgesic effects. In this study, we examined the anti-inflammatory and analgesic effects of combining celecoxib with Shinbaro in a complete Freund's adjuvant (CFA)-induced inflammatory pain model.</p><p><strong>Methods: </strong>We randomly assigned 66 mice to 6 groups (n = 11 per group) and administered intraplantar injections of 100 μL CFA or saline into their right hind paw, followed by oral administration of Shinbaro (100 mg/kg), celecoxib (15 or 30 mg/kg), or both 30 minutes later. Behavioral assessments were conducted blindly at baseline and on days 1, 3, and 7 post-injection. The right hind paw and spinal cord were harvested 3 days post-injection to examine the molecular mechanisms, including macrophage infiltration in the right hind paw, as well as glial cell activation and inflammatory cytokine levels in the spinal cord. Statistical analysis was performed using Tukey's post-hoc test.</p><p><strong>Results: </strong>The combination of Shinbaro (100 mg/kg) and celecoxib (15 mg/kg) synergistically reduced mechanical hyperalgesia and paw edema by preventing the conversion of monocytes to macrophages and inhibiting macrophage infiltration. Moreover, it decreased the expression of pro-inflammatory cytokines and mediators in the spinal cord by inhibiting spinal microglial activation.</p><p><strong>Conclusion: </strong>The combination of Shinbaro and celecoxib demonstrates significant anti-inflammatory and analgesic effects, suggesting its potential for managing inflammatory pain with fewer side effects than conventional therapies.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2349-2362"},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SIL-TAL1-Positive Adult T-ALL with t(11;14)(p15;q11.2): A Rare Case Report Highlighting Prognostic Challenges and Treatment Implications.","authors":"Siyu Chen, Shengwang Wu, Nan Li, Xing Qiang, Yongjie Tang, Yimei Feng, Cheng Zhang, Xiangui Peng, Shuiqing Liu, Xi Zhang","doi":"10.2147/JIR.S497615","DOIUrl":"10.2147/JIR.S497615","url":null,"abstract":"<p><p>T-cell acute lymphoblastic leukemia (T-ALL) with coexisting SIL-TAL1 fusion and t(11;14)(p15;q11.2) is exceedingly rare. There are limited data on the clinical course and outcomes of such patients. We report a case of a 19-year-old male presenting with aggressive T-ALL harboring these abnormalities, along with NOTCH1 and PTEN mutations. SIL-TAL1 positivity is associated with poor prognosis in T-ALL. Despite achieving remission with intensive chemotherapy, the patient experienced rapid relapse and poor overall survival, reflecting the ineffectiveness of conventional treatments. The findings highlight the synergistic role of SIL-TAL1 and t(11;14) in disease progression and underscore the urgent need for targeted therapies and immunotherapies to improve outcomes in such high-risk cases.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2339-2347"},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abnormal CSF-Specific OCBs in Neuronal Surface Antibody-Associated Autoimmune Encephalitis Differentiating from Viral Encephalitis.","authors":"Shan Qiao, Chong Zhang, Haiyun Li, Tianyu Zhou, Aihua Wang, Shanchao Zhang","doi":"10.2147/JIR.S504003","DOIUrl":"10.2147/JIR.S504003","url":null,"abstract":"<p><strong>Purpose: </strong>The present study aimed to examine the clinical distinctions among patients with neuronal surface antibody-associated autoimmune encephalitis (NSAE) diagnosed with anti-N-methyl-D-aspartate receptor encephalitis (NMDAR-E), anti-leucine-rich glioma-inactivated 1 encephalitis (LGI1-E), and anti-gamma aminobutyric acid-B receptor encephalitis (GABABR-E), compared with those with viral encephalitis (VE). Additionally, the study aimed to assess the impact of cerebrospinal fluid (CSF) oligoclonal bands (OCBs) on the severity and prognosis of NSAE.</p><p><strong>Patients and methods: </strong>This retrospective analysis included patients with NSAE, encompassing NMDAR-E, LGI1-E, and GABABR-E, alongside individuals with VE. Participants with NSAE were categorized into two groups based on the presence or absence of CSF-specific OCBs. Data regarding demographics, clinical manifestations, magnetic resonance imaging (MRI) findings, CSF analyses and prognosis were collected and analyzed.</p><p><strong>Results: </strong>The findings indicated that younger female with NSAE exhibited a higher incidence of seizure onset, disruption of the blood-CSF barrier (BCSFB), and elevated Q_Alb/Q_Lim ratios compared to VE patients, with NSAE patients demonstrating more severe clinical outcomes at discharge. Among the 185 NSAE patients, 43 (23.24%) were positive for OCBs, while 142 (76.76%) negative. The OCB-positive cohort displayed a greater prevalence of younger females and NMDAR-E (both P<0.05). No significant differences were observed in CSF white blood cell counts, protein concentrations, or immunoglobulin G levels between the two groups (all P>0.05). The modified Rankin Scale (mRS) scores at discharge and the final follow-up were higher in the OCB-positive group than the OCB-negative group (both P<0.05). Both univariate and multivariate analyses identified OCBs and NSAE subtypes as independent risk factors influencing the clinical prognosis of NSAE.</p><p><strong>Conclusion: </strong>In comparison to VE patients, NSAE patients with positive OCBs were more frequently female and exhibited CSF pleocytosis, particularly among those with NMDAR-E. Importantly, the presence of positive OCBs emerged as an independent predictor of unfavorable outcomes in patients with NMDAR-E, LGI1-E, and GABABR-E.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2307-2316"},"PeriodicalIF":4.2,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complexation of α-Mangostin with γ-Cyclodextrin and Its Application in Alginate/Chitosan Hydrogel Mucoadhesive Film for Treatment of Recurrent Aphthous Stomatitis.","authors":"Ine Suharyani, Ahmed Fouad Abdelwahab Mohammed, Muchtaridi Muchtaridi, Ali El-Rayyes, Marline Abdassah, Cecep Suhandi, Nasrul Wathoni","doi":"10.2147/JIR.S482582","DOIUrl":"10.2147/JIR.S482582","url":null,"abstract":"<p><strong>Introduction: </strong>α-Mangostin (α-M), one of the xanthon compound isolated from <i>Garcinia mangostana</i> rind, demonstrates the efficacy in the treatment of recurrent aphthous stomatitis (RAS). The lack of solubility of α-mangostin in water limited its pharmacological application.</p><p><strong>Purpose: </strong>The lack of solubility of α-mangostin in water limited its formulation and pharmacological application. This study was done to enhance the solubility of α-M by complexation with γ-cyclodextrin (γ-CD) and its application in Alginate/Chitosan Hydrogel Mucoadhesive Film (HMF) for RAS treatment.</p><p><strong>Methods: </strong>This complex was made by dissolved α-M and γ-CD in separated solution. α-M solution gradualy added into γ-CD to formed α-M/γ-CD complex (α-M/γ-CD CX). This complex then evaporated to yield the dry complex powder. The complex was successfully formulated into hydrogel mucoadhesive film (HMF) preparations based on characterization using Scanning Electron Microscope (SEM), Fourier Transform Infra-Red (FTIR), and X-Ray Diffractometry (XRD). The complex was formulated in hydrogel mucoadhesive film, followed by in-vitro drug release and the study of recurrent aphthous stomatitis (RAS) activity in rats.</p><p><strong>Results: </strong>The α-M/γ-CD CX HMF film has a higher mucoadhesive force and mucoadhesive time than other HMFs resulting in a prolonged retention time in the oral mucosa. The drug release of α-M/γ-CD CX HMF followed the Korsmeyer-Peppas Model with a total amount of drug released 80.34+0.32%. The inclusion complex of α-M/γ-CD CX HMF exhibited increased anti-RAS activity compared to HMF base, α-M HMF, and α-M/γ-CD PM HMF. This was evidenced by a significant decrease in wound area of approximately 79.05±3.30%, an increase in epithelial thickness of about 1.24±0.09 μm, and a decrease in neutrophil score 1.10±0.26. These findings highlight the potential use of α-M/γ-CD CX as an effective RAS agent in HMF.</p><p><strong>Conclusion: </strong>The complex of α-M/γ-CD CX has improved solubility of α-M, resulting in the transparent and homogenous film. The film containing this complex has the better physical characteristic, increasing the release and RAS activity.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2185-2204"},"PeriodicalIF":4.2,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs With Response to Treatment With Dupilumab in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis\" [Letter].","authors":"Yingjian Tan, Rui Li","doi":"10.2147/JIR.S520083","DOIUrl":"10.2147/JIR.S520083","url":null,"abstract":"","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2283-2284"},"PeriodicalIF":4.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic Changes in Complement Proteins in the Aqueous Humor and Plasma of Patients Undergoing Ranibizumab Treatment for Retinal Vein Occlusion: A Need for Further Research [Letter].","authors":"Dongrui Liang, Xiaodong Li","doi":"10.2147/JIR.S520197","DOIUrl":"10.2147/JIR.S520197","url":null,"abstract":"","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2285-2286"},"PeriodicalIF":4.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS).","authors":"Dacheng Xiong, Huixian Geng, Xuechun Lv, Shuqi Wang, Lijing Jia","doi":"10.2147/JIR.S504694","DOIUrl":"10.2147/JIR.S504694","url":null,"abstract":"<p><p>Many patients now survive their initial critical events but subsequently develop chronic critical illness (CCI). CCI is characterized by prolonged hospital stays, poor outcomes, and significant long-term mortality. The incidence of chronic critical illness (CCI) is estimated to be 34.4 cases per 100,000 population. The incidence varies significantly with age, peaking at 82.1 cases per 100,000 in individuals aged 75-79. The one-year mortality rate among CCI patients approaches 50%. A subset of these patients enters a state of persistent inflammation, immune suppression, and ongoing catabolism, a condition termed persistent inflammation, immunosuppression, and catabolism syndrome (PICS) in 2012. In recent years, some progress has been made in treating PICS. For instance, recent advancements such as the persistent expansion of MDSCs (myeloid-derived suppressor cells) and the mechanisms underlying intestinal barrier dysfunction have provided new directions for therapeutic strategies, as discussed below. Persistent inflammation, a key feature of PICS, has received comparatively little research attention. In this review, we examine the potential pathophysiological changes and molecular mechanisms underlying persistent inflammation and its role in PICS. We also discuss current therapies about inflammation and offer recommendations for managing patients with PICS.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2267-2281"},"PeriodicalIF":4.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying Therapeutic Targets and Potential Drugs for Diabetic Retinopathy: Focus on Oxidative Stress and Immune Infiltration.","authors":"Hongsong Peng, Qiang Hu, Xue Zhang, Jiayang Huang, Shan Luo, Yiming Zhang, Bo Jiang, Dawei Sun","doi":"10.2147/JIR.S500214","DOIUrl":"10.2147/JIR.S500214","url":null,"abstract":"<p><strong>Background: </strong>Diabetic retinopathy (DR), a microvascular disorder linked to diabetes, is on the rise globally. Oxidative stress and immune cell infiltration are linked to illness initiation and progression, according to recent study. This study investigated biomarkers connected to DR and oxidative stress and their connection with immune cell infiltration using bioinformatics analysis and found possible therapeutic medications.</p><p><strong>Methods: </strong>The Gene Expression Omnibus (GEO) database was used to obtain the gene expression data for DR. Differentially expressed genes (DEGs) and oxidative stress (OS)-related genes were intersected. The Enrichment analyses concentrate on OS-related differentially expressed genes (DEOSGs). Analysis of protein-protein interaction (PPI) networks and machine learning algorithms were used to identify hub genes. Single-gene Gene Set Enrichment Analysis (GSEA) identified biological functions, while nomograms and ROC curves assessed diagnostic potential. Immune infiltration analysis and regulatory networks were constructed. Drug prediction was validated through molecular docking, and hub gene expression was confirmed in dataset and animal models.</p><p><strong>Results: </strong>Compared to the control group, 91 DEOSGs were found. Enrichment analyses showed that these DEOSGs were largely connected to oxidative stress response, PI3K/Akt pathway, inflammatory pathways, and immunological activation. Four hub genes were found via PPI networks and machine learning. These hub genes were diagnostically promising according to nomogram and ROC analysis. Analysis of immune cell infiltration highlighted the role of immune cells. Gene regulatory networks for transcription factor (TF) and miRNA were created. Using structural data, molecular docking shows potential drugs and hub genes have high binding affinity. Dataset analysis, Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) and Western Blot (WB) confirmed the CCL4 expression difference between DR and controls.</p><p><strong>Conclusion: </strong>CCL4 was identified as potential oxidative stress-related biomarker in DR, providing new insights for DR diagnosis and treatment.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2205-2227"},"PeriodicalIF":4.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury.","authors":"Qi Shi, Tingting Hu, Lixia Xu, Jiayuanyuan Fu, Yehong Fang, Yu Lan, Weijia Fan, Qiaoli Wu, Xiaoguang Tong, Hua Yan","doi":"10.2147/JIR.S503428","DOIUrl":"10.2147/JIR.S503428","url":null,"abstract":"<p><strong>Background: </strong>Acute lung injury (ALI) is a serious yet common complication in patients with traumatic brain injury (TBI), often associated with poor prognosis. The development of TBI-induced ALI is closely associated with excessive oxidative stress and NLRP3 inflammasome activation. Fingolimod, an immunomodulatory agent, has been reported to attenuate inflammatory responses, restore blood-brain barrier integrity, reduce cerebral edema, and mitigate associated neurological deficits.</p><p><strong>Objective: </strong>This study aimed to investigate the mechanistic role of NLRP3 inflammasome activation in TBI-induced ALI and to evaluate the therapeutic potential of fingolimod in targeting this inflammatory pathway.</p><p><strong>Results: </strong>A rat TBI model was established using the classical free-fall method, and animals were treated with fingolimod (0.5 or 1 mg/kg) daily for three days. The TBI model rats presented with clear signs of histopathological pulmonary damage, an increase in the permeability of capillaries in the lung, and pulmonary edema that coincided with significantly increased NLRP3, caspase-1, and ASC expression in lung tissue samples. This overexpression of NLRP3 inflammasome machinery resulted in the release of IL-1β. Fingolimod treatment, however, reversed all of these effects such that it suppressed NLRP3 activity and normalized levels of IL-1β, leading to the alleviation of inflammation. In line with these results, LPS and nigericin (NLRP3 agonist)-treated NR8383 cells treated using fingolimod exhibited reductions in reactive oxygen species production and NLRP3 inflammasome activation.</p><p><strong>Conclusion: </strong>These findings suggest that NLRP3 inflammasome activation and oxidative stress are key mediators of TBI-induced ALI. Fingolimod exerts protective effects against this condition by inhibiting NLRP3 inflammasome activation, highlighting its potential as a therapeutic agent for TBI-associated pulmonary complications.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2229-2245"},"PeriodicalIF":4.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11835775/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SPP1 as a Prognostic and Immunotherapeutic Biomarker in Gliomas and Other Cancer Types: A Pan-Cancer Study.","authors":"Kan Wang, Jinxin Wan, Ruipeng Zheng, Yifei Xiao, Fengjun Lv, Haitao Ge, Guang Yang, Yu Cheng","doi":"10.2147/JIR.S505237","DOIUrl":"10.2147/JIR.S505237","url":null,"abstract":"<p><strong>Background: </strong>Gliomas, including glioblastoma (GBM), present significant treatment challenges due to their poor prognosis and complex tumor microenvironment. This study investigates the role of Secreted Phosphoprotein 1 (SPP1) as a prognostic and immunotherapeutic biomarker in gliomas and other cancers through pan-cancer analysis.</p><p><strong>Methods: </strong>A comprehensive pan-cancer analysis was conducted using datasets from UCSC TCGA Pan-Cancer, TCGA-GBM, UALCAN, and single-cell sequencing data from GEO and TISCH. The correlation of SPP1 expression with overall survival (OS), progression-free survival (PFS), immune cell infiltration, and immune checkpoint markers was analyzed. Functional validation was performed via SPP1 knockdown in glioma cell lines to evaluate effects on proliferation, invasion, and immune interactions.</p><p><strong>Results: </strong>SPP1 was found to be overexpressed in 27 tumor types, with high expression correlating with poor OS, PFS, and increased immune cell infiltration, particularly with CD8+ T cells and macrophages. Single-cell analysis indicated SPP1 enrichment in macrophages interacting with malignant GBM cells. Knockdown of SPP1 significantly inhibited glioma cell proliferation, invasion, and promoted apoptosis.</p><p><strong>Conclusion: </strong>The findings suggest that SPP1 is a promising target for immunotherapy, potentially improving outcomes for patients with gliomas and other cancers. Further research is warranted to explore SPP1-targeted therapies and their efficacy in clinical settings.</p>","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"2247-2265"},"PeriodicalIF":4.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}